Drucken

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

BOSTON --(BUSINESS WIRE)-- 10.10.2024 --

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Third Quarter 2024 Earnings Call."

The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases - cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia - and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and X.

(VRTX-WEB)

Vertex Pharmaceuticals Incorporated Investor Relations:
investorinfo@vrtx.com

Business Wire

Zeit Meldung
12:07 BUSINESS WIRE: Rawbank Reports Strong 2024 Perform
12:01 BUSINESS WIRE: LiveDrop sichert sich 2,5 Millionen
07:00 BUSINESS WIRE: Combined Shareholders’ Meeting of J
00:02 BUSINESS WIRE: Gurobi startet Innovation Lab zur F
19.06. BUSINESS WIRE: Grid Dynamics stellt auf der Automa
19.06. BUSINESS WIRE: Helm.ai kündigt Level 3-System für
19.06. BUSINESS WIRE: Sigma7 gibt Partnerschaft mit R24 I
19.06. BUSINESS WIRE: Experian beschleunigt Migration zu
19.06. BUSINESS WIRE: Neue für Fahrzeuge geeignete Chip-F
19.06. BUSINESS WIRE: LTIMindtree bringt mit ‘BlueVerse’
19.06. BUSINESS WIRE: Ares Management lanciert ersten ELT
19.06. BUSINESS WIRE: Passwork stärkt das Engagement für
19.06. BUSINESS WIRE: Chiesi Global Rare Diseases vergibt
19.06. BUSINESS WIRE: Brenus Pharma und InSphero haben 3D
19.06. BUSINESS WIRE: Incyte gibt FDA-Zulassung für Monju
19.06. BUSINESS WIRE: KIKO Milano kooperiert mit Logistic
19.06. BUSINESS WIRE: Textron Aviation Defense und Thai A
19.06. BUSINESS WIRE: Alipay+ Launches World’s First Smar
19.06. BUSINESS WIRE: LabPMM® erhält Zulassung des Staate
19.06. BUSINESS WIRE: LambdaTest gewinnt 2025 Digital Inn
19.06. BUSINESS WIRE: Der Log Explorer von Cloudflare sta
19.06. BUSINESS WIRE: Stone Harbor Investment Partners st
19.06. BUSINESS WIRE: Ververica gibt Partnerschaft mit Ai
19.06. BUSINESS WIRE: Indien ist Gastgeber des ersten Wor
18.06. BUSINESS WIRE: Veracode von Tecnimont Services (MA

Mehr Marktdaten und Kurse finden Sie auf www.finanztreff.de

Angebote der
Nutzungshinweise | Datenschutz | Impressum | Datenquellen: boerse-stuttgart.de,